Selected article for: "cc international license and severe disease"

Author: Andrew Clark; Mark Jit; Charlotte Warren-Gash; Bruce Guthrie; Harry HX Wang; Stewart W Mercer; Colin Sanderson; Martin McKee; Christopher Troeger; Kanyin I Ong; Francesco Checchi; Pablo Perel; Sarah Joseph; Hamish P Gibbs; Amitava Banerjee; Rosalind M Eggo
Title: How many are at increased risk of severe COVID-19 disease? Rapid global, regional and national estimates for 2020
  • Document date: 2020_4_22
  • ID: czuq8rw5_56
    Snippet: With the exception of HIV/AIDS our estimates do not account for the role of treatment or control of the underlying condition: for example, while some conditions are less prevalent in Africa than Europe, African patients may on average be at higher risk as they have less access to diagnosis and effective treatment. It is not yet known whether those with HIV are at increased risk of severe disease with COVID-19. Whilst it has been shown that widesp.....
    Document: With the exception of HIV/AIDS our estimates do not account for the role of treatment or control of the underlying condition: for example, while some conditions are less prevalent in Africa than Europe, African patients may on average be at higher risk as they have less access to diagnosis and effective treatment. It is not yet known whether those with HIV are at increased risk of severe disease with COVID-19. Whilst it has been shown that widespread introduction of ART reduced the risk of hospitalisation and death associated with seasonal influenza, 36 a substantial proportion of those on ART remain somewhat immunocompromised. 37, 38 Recent evidence from South Africa has shown that individuals living with HIV have an eight-fold higher risk of pneumonia hospitalisation associated with seasonal influenza, and a three-fold higher risk of pneumonia death. 39 Until more evidence emerges, it may be necessary to include these individuals in shielding strategies, irrespective of ART status, with priority given to those not yet receiving treatment. 40 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • art status and high risk: 1, 2, 3
    • control treatment and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • control treatment and HIV live: 1
    • control treatment and increase risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • control treatment and international license: 1, 2, 3, 4, 5, 6, 7
    • control treatment and pneumonia death: 1, 2, 3
    • control treatment and recent evidence: 1, 2, 3, 4, 5
    • control treatment and seasonal influenza: 1, 2, 3, 4, 5, 6
    • death hospitalisation and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • death hospitalisation and increase risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • death hospitalisation and individual include: 1
    • death hospitalisation and pneumonia death: 1, 2, 3, 4
    • death hospitalisation and pneumonia hospitalisation: 1, 2, 3, 4, 5
    • death hospitalisation and recent evidence: 1
    • death hospitalisation and seasonal influenza: 1, 2
    • effective treatment and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • effective treatment and HIV live: 1, 2
    • effective treatment and increase risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • effective treatment and international license: 1, 2, 3, 4, 5, 6, 7, 8, 9